{"gene":"CDK13","run_date":"2026-06-09T22:57:18","timeline":{"discoveries":[{"year":2015,"finding":"CDK13 forms a complex with Cyclin K and phosphorylates both Ser2 and Ser5 of the RNA polymerase II CTD, with a preference for substrates bearing Ser7 pre-phosphorylation at a C-terminal position. The crystal structure of Cdk13/CyclinK was determined at 2.0 Å resolution, revealing a C-terminal extension helix with a polybasic cluster and a DCHEL motif that interacts with bound ATP.","method":"Crystal structure determination (2.0 Å), in vitro kinase assays with recombinant proteins","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure combined with in vitro kinase activity assays in a single rigorous study","pmids":["26748711"],"is_preprint":false},{"year":2015,"finding":"CDK13, isolated as a Flag-tagged complex, associates with numerous RNA processing factors. Knockdown of CDK13 or its cyclin partner CCNK preferentially affects expression of snoRNA genes and leads to defects in RNA processing, and CDK13 physically interacts with RNA processing factors.","method":"Flag-tag affinity purification/mass spectrometry, RNA-seq, siRNA knockdown","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal AP-MS identification of interactors combined with transcriptomic knockdown phenotype, single lab but two orthogonal methods","pmids":["25561469"],"is_preprint":false},{"year":2007,"finding":"CDK13 (CDC2L5) interacts with L-type cyclins (Cyclin L1/L2) via its kinase domain; CDK13 and L-type cyclins modulate each other's subcellular localization. Overexpression of CDK13 alters the splicing pattern of E1a minigene reporter transcripts in a dose-dependent manner, and this effect is counteracted by SF2/ASF and SC35.","method":"Co-immunoprecipitation, subcellular localization imaging, minigene splicing reporter assay in HEK293T cells","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — single Co-IP plus functional splicing assay, single lab, two orthogonal methods","pmids":["17261272"],"is_preprint":false},{"year":2006,"finding":"CDK13 (CDC2L5) localizes to the nucleoplasm, with enrichment in nuclear speckles dependent on the N-terminal RS domain. CDK13 directly interacts with the ASF/SF2-associated protein p32. Overexpression of CDK13 constructs disturbs constitutive splicing and switches alternative splice site selection in vivo.","method":"Subcellular fractionation/immunofluorescence, in vitro GST pulldown, in vivo splicing assays","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding assay plus localization experiment with functional splice-site consequence, single lab","pmids":["16721827"],"is_preprint":false},{"year":2008,"finding":"CDK13 interacts with HIV-1 Tat both in vivo (co-immunoprecipitation) and in vitro. CDK13 increases HIV-1 mRNA splicing, favors production of the doubly spliced Nef protein, decreases production of viral proteins Gag and Env, and suppresses virus production. CDK13 mediates its effect on splicing through phosphorylation of ASF/SF2.","method":"Co-immunoprecipitation, in vitro binding, siRNA knockdown, viral production assays, splicing assays","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, functional siRNA rescue, and splicing mechanistic follow-up, single lab","pmids":["18480452"],"is_preprint":false},{"year":2016,"finding":"THZ531, a covalent inhibitor, irreversibly targets a cysteine residue located outside the kinase domain of CDK12 (and by analogy CDK13, as revealed by co-crystallization with CDK12–Cyclin K). THZ531 causes loss of elongating and hyperphosphorylated RNA Pol II and substantially decreases expression of DNA damage response genes and super-enhancer-associated transcription factor genes.","method":"Co-crystallization, covalent inhibitor design, RNA-seq, Western blot","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — structural co-crystallization with functional transcriptomic validation; CDK13 inhibition confirmed alongside CDK12","pmids":["27571479"],"is_preprint":false},{"year":2020,"finding":"CDK13 and CDK12 are substantially redundant regulators of global RNA Pol II processivity and transcription elongation. Single inhibition of CDK13 induces transcriptional changes associated with cellular growth signaling pathways with minimal effects on cell viability; dual CDK12/CDK13 inhibition potently induces cell death associated with widespread use of alternative 3′ polyadenylation sites, loss of POLII CTD phosphorylation, and greatly reduced POLII elongation rates.","method":"CRISPR-Cas9 analog-sensitive kinase alleles, RNA-seq, POLII ChIP-seq, cell viability assays","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 2 / Strong — analog-sensitive kinase system (highly specific), genome-wide transcriptomic and ChIP analyses, mechanistic epistasis between CDK12 and CDK13","pmids":["32917631"],"is_preprint":false},{"year":2019,"finding":"Inhibition or loss of CDK12/CDK13 triggers intronic polyadenylation site cleavage that suppresses expression of core DNA damage response proteins, creating a BRCAness phenotype with deficiencies in DNA damage repair.","method":"siRNA knockdown, CDK12/13 inhibitor SR-4835, RNA-seq, intronic polyadenylation analysis, DNA damage repair assays","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (genetic KD and pharmacological inhibition), genome-wide RNA-seq, functional DNA repair assay","pmids":["31668947"],"is_preprint":false},{"year":2023,"finding":"CDK13 is required for ZC3H14 phosphorylation, which is necessary and sufficient to promote nuclear RNA degradation. Mutant CDK13 (patient melanoma mutations) fails to activate nuclear RNA surveillance, causing aberrant protein-coding transcripts to be stabilized and translated.","method":"Zebrafish melanoma model, phosphorylation assays, RNA stabilization measurements, forced aberrant RNA expression","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo zebrafish disease model, identification of direct substrate ZC3H14, rescue/sufficiency experiments with multiple orthogonal approaches","pmids":["37079685"],"is_preprint":false},{"year":2023,"finding":"CDK13 directly phosphorylates translation initiation factors 4E-BP1 (at Thr46) and eIF4B (at Ser422). CDK13 inhibition disrupts mRNA translation and reduces MYC oncoprotein synthesis in colorectal cancer cells. CDK13 and mTORC1 have additive effects on 4E-BP1/eIF4B phosphorylation.","method":"In vitro kinase assay, site-specific mutagenesis, polysome profiling, pharmacological inhibition, Western blot","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay with mutagenesis identifying phosphorylation sites, polysome profiling as orthogonal functional readout, single lab","pmids":["36882522"],"is_preprint":false},{"year":2023,"finding":"CDK13 interacts with and phosphorylates RNA methyltransferase NSUN5 at Ser327. Phosphorylated NSUN5 catalyzes m5C modification of ACC1 mRNA; the m5C-modified ACC1 mRNA binds ALYREF to enhance mRNA stability and nuclear export, increasing ACC1 expression and lipid deposition in prostate cancer cells.","method":"Co-immunoprecipitation, in vitro kinase assay, m5C RNA methylation profiling, mRNA stability assays, gain/loss-of-function studies","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus in vitro kinase assay with identified phosphorylation site and downstream m5C functional consequence, single lab","pmids":["37845385"],"is_preprint":false},{"year":2021,"finding":"CDK13 interacts with E2F5; this interaction promotes PCa cell proliferation. Transcriptional activation of endogenous CDK13 promotes E2F5 protein expression by facilitating circCDK13 formation (note: the circCDK13-miRNA sponge mechanism is a non-protein product; the CDK13–E2F5 protein interaction is the canonical mechanistic finding here).","method":"Co-immunoprecipitation coupled with mass spectrometry, loss-of-function and gain-of-function assays","journal":"Journal of experimental & clinical cancer research : CR","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single Co-IP/MS identification of E2F5 interaction, single lab, no biochemical reconstitution","pmids":["33390186"],"is_preprint":false},{"year":2021,"finding":"HIV-1 Nef recruits the Cyclin K/CDK13 complex (identified by affinity purification/mass spectrometry). CycK/CDK13 phosphorylates SERINC5 at Ser360, and this phosphorylation is required for Nef-mediated downregulation of SERINC5 from the cell surface and suppression of its antiviral activity. S360 phosphorylation increases Nef–SERINC5 interaction.","method":"Affinity purification/mass spectrometry, in vitro kinase assay, chimeric CD8-SERINC5 constructs, flow cytometry, viral infectivity assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — AP-MS complex identification followed by in vitro kinase assay with mutagenesis (S360A), functional rescue experiments, mechanistic chain established","pmids":["34380030"],"is_preprint":false},{"year":2014,"finding":"Knockdown of Cdk13 in neuronal models (P19 cells and primary cortical neurons) reduces axonal elongation. Cdk13 depletion significantly reduces Cdk5 expression at both mRNA and protein levels. Overexpression of Cdk5 partially rescues the neurite outgrowth defect caused by Cdk13 depletion, placing Cdk13 upstream of Cdk5 in a common signaling pathway.","method":"siRNA knockdown, in situ hybridization, Western blot, microarray, Cdk5 overexpression rescue, P19 neuronal differentiation model","journal":"Experimental neurology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis by rescue experiment (Cdk5 OE rescues Cdk13 KD), multiple readouts, single lab","pmids":["24999027"],"is_preprint":false},{"year":2016,"finding":"CDK13 is enriched in the perinucleolar compartment (PNC) throughout the cell cycle, co-localizing with PTB. Neither Cyclin K, Cyclin L (known CDK13 partners), nor CDK13's potential kinase substrates accumulate in PNC. CDK13 overexpression increases PNC prevalence, suggesting CDK13 contributes to PNC formation.","method":"Immunofluorescence microscopy, co-localization analysis, PNC prevalence quantification","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct localization by immunofluorescence with functional consequence (PNC prevalence), single lab, replicated across cell cycle stages","pmids":["26886422"],"is_preprint":false},{"year":2021,"finding":"An ADAR1-dependent A-to-I RNA editing event in the CDK13 coding region (c.308A>G) promotes cancer cell hallmarks (viability, proliferation, invasion). This editing event increases the nucleolar abundance of CDK13 protein and may explain ADAR1-dependent global splicing changes.","method":"Whole transcriptome sequencing, RNA editing validation, functional cell assays, subnuclear localization microscopy, gene silencing","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — editing site identified by sequencing and validated, subcellular localization shift shown by imaging with functional consequence, single lab","pmids":["34496885"],"is_preprint":false},{"year":2023,"finding":"CDK13 inhibition by AR-A014418 represses transcription of PD-L1. CDK12 inhibition by the same compound enhances intronic polyadenylation (IPA) of PD-L1, generating a secreted isoform. Dual CDK12/CDK13 inhibition dramatically suppresses full-length PD-L1. These roles were confirmed by RNA interference and protein overexpression of CDK12 and CDK13 individually.","method":"In vitro kinase assay with recombinant proteins, RNA interference, protein overexpression, qRT-PCR, Western blot, flow cytometry","journal":"Journal for immunotherapy of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro kinase confirmation plus RNAi/OE dissection of CDK13-specific transcriptional role, single lab","pmids":["37164450"],"is_preprint":false},{"year":2024,"finding":"CDK13 inactivation drives genomic instability via transcription-replication conflicts. CDK12-mutant organoids and patient-derived xenografts are sensitive to CDK13 inhibition or degradation, establishing synthetic lethality between CDK12 loss and CDK13 inhibition.","method":"CRISPR knockout, organoid models, patient-derived xenografts, CDK13 inhibitor/degrader treatment, transcription-replication conflict assays","journal":"Cell reports. Medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo PDX models plus mechanistic transcription-replication conflict assays, single lab","pmids":["39368479"],"is_preprint":false},{"year":2023,"finding":"The inhibitor SR-4835 binding to CDK12/CDK13 greatly destabilizes their interaction with Cyclin K in an allosteric manner (not simply active-site competition), as revealed by lysine reactivity profiling and native mass spectrometry.","method":"Structural mass spectrometry (lysine reactivity profiling + native MS)","journal":"Journal of the American Chemical Society","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two orthogonal structural MS methods revealing allosteric mechanism, single lab","pmids":["37207290"],"is_preprint":false},{"year":2026,"finding":"CDK13 directly phosphorylates METTL16 at Ser329, augmenting its catalytic activity to install m6A modifications on ACLY mRNA. These m6A marks are recognized by YTHDC2, stabilizing ACLY mRNA and increasing acetyl-CoA production to fuel lipogenesis in clear cell renal cell carcinoma.","method":"In vitro kinase assay, m6A profiling, mRNA stability assays, gain/loss-of-function, in vivo xenograft models","journal":"Experimental & molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro kinase assay identifying phosphorylation site plus m6A functional axis, single lab","pmids":["41680470"],"is_preprint":false},{"year":2026,"finding":"CDK13 directly phosphorylates RBM39 at Ser117. This phosphorylation enhances RBM39 binding to and stabilization of RAD50 mRNA, increasing RAD50 protein levels and promoting DNA damage repair, thereby conferring cisplatin resistance in endometrial cancer.","method":"Phosphoproteomic analysis, in vitro kinase assay, RNA binding/stability assays, loss-of-function studies, in vivo xenograft models","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phosphoproteomic identification followed by direct in vitro kinase validation and mRNA stabilization assays, single lab","pmids":["41997449"],"is_preprint":false},{"year":2023,"finding":"Cyclin O (CCNO) interacts with CDK13 (by co-immunoprecipitation) and promotes proliferation signaling activation in lung adenocarcinoma; a CDK13 inhibitor abrogates the oncological effect of CCNO overexpression.","method":"Co-immunoprecipitation, Western blot, CDK13 inhibitor treatment, xenograft model","journal":"Journal of thoracic disease","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single Co-IP identifying CCNO-CDK13 interaction, single lab, no biochemical reconstitution of the complex","pmids":["37197505"],"is_preprint":false},{"year":2026,"finding":"CDK12/CDK13 inhibition in glioblastoma stem cells (GSCs) causes rapid, genome-wide loss of RNAPII CTD Ser2 phosphorylation, abolishing transcriptional elongation. Unexpectedly, CDK12/CDK13 inhibition also arrests DNA replication fork progression, preceding DNA damage response activation, directly linking RNAPII elongation to replication fork dynamics.","method":"CDK12/13 inhibitor treatment, RNAPII pSer2 ChIP-seq, DNA replication fork assays, RNA-seq, xenograft models","journal":"EMBO molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genome-wide ChIP-seq plus orthogonal replication fork assays establishing mechanistic link, single lab","pmids":["41882177"],"is_preprint":false}],"current_model":"CDK13 is a transcriptional cyclin-dependent kinase that forms an active heterodimer with Cyclin K; it phosphorylates Ser2 and Ser5 of the RNA Pol II CTD to promote transcriptional elongation and processivity (redundantly with CDK12), regulates alternative splicing and RNA processing through interactions with SR proteins and RNA processing factors, phosphorylates ZC3H14 to activate nuclear RNA surveillance, and directly phosphorylates non-transcriptional substrates including translation initiation factors 4E-BP1/eIF4B, the RNA methyltransferases NSUN5 and METTL16, and the RNA-binding protein RBM39, thereby linking CDK13 kinase activity to control of mRNA translation, m5C/m6A epitranscriptomic modification, and mRNA stability."},"narrative":{"mechanistic_narrative":"CDK13 is a transcriptional cyclin-dependent kinase that pairs with Cyclin K to phosphorylate Ser2 and Ser5 of the RNA polymerase II C-terminal domain, driving transcriptional elongation and processivity [PMID:26748711]. Its crystal structure with Cyclin K reveals a C-terminal extension helix bearing a polybasic cluster and a DCHEL motif that contacts bound ATP [PMID:26748711]. CDK13 functions largely redundantly with CDK12 in controlling global Pol II elongation: single CDK13 inhibition perturbs growth-signaling transcripts with little effect on viability, whereas dual CDK12/CDK13 inhibition collapses CTD phosphorylation, slows elongation, and triggers widespread alternative 3' polyadenylation and cell death [PMID:32917631]. Loss of CDK12/CDK13 activity promotes intronic polyadenylation that truncates DNA damage response genes, producing a BRCAness phenotype, and drives genomic instability through transcription–replication conflicts and stalled replication forks [PMID:31668947, PMID:41882177], a vulnerability that underlies synthetic lethality between CDK12 loss and CDK13 inhibition [PMID:39368479]. Beyond elongation, CDK13 shapes RNA processing and splicing through association with RNA processing factors and SR proteins: it interacts with the ASF/SF2-associated protein p32, localizes to nuclear speckles via its N-terminal RS domain, and alters splice-site selection [PMID:25561469, PMID:16721827], and it activates nuclear RNA surveillance by phosphorylating ZC3H14 to promote degradation of aberrant transcripts [PMID:37079685]. CDK13 additionally phosphorylates non-transcriptional substrates, including the translation factors 4E-BP1 (Thr46) and eIF4B (Ser422) to control mRNA translation and MYC synthesis [PMID:36882522], the RNA methyltransferases NSUN5 (Ser327) and METTL16 (Ser329) to direct m5C and m6A modifications that stabilize lipogenic mRNAs [PMID:37845385, PMID:41680470], and RBM39 (Ser117) to stabilize RAD50 mRNA and promote DNA repair [PMID:41997449]. CDK13 is also exploited by HIV-1, where the Cyclin K/CDK13 complex phosphorylates SERINC5 (Ser360) to enable Nef-mediated antagonism of this antiviral factor [PMID:34380030].","teleology":[{"year":2006,"claim":"Established CDK13 as a nuclear speckle-associated factor whose RS domain governs localization and whose activity influences constitutive and alternative splicing, framing it as a splicing regulator before its kinase partner was defined.","evidence":"Subcellular fractionation/immunofluorescence, GST pulldown with p32, and in vivo splicing assays","pmids":["16721827"],"confidence":"Medium","gaps":["Did not identify the catalytic substrate driving splice-site switching","Cyclin partner and kinase activity not established here"]},{"year":2007,"claim":"Identified L-type cyclins as CDK13 binding partners through its kinase domain and showed dose-dependent splicing modulation counteracted by SR proteins, connecting CDK13 to the SR protein splicing machinery.","evidence":"Co-immunoprecipitation, localization imaging, and E1a minigene splicing reporter in HEK293T","pmids":["17261272"],"confidence":"Medium","gaps":["Direct phosphorylation of SR proteins not demonstrated","Functional relevance of Cyclin L versus Cyclin K complexes unresolved"]},{"year":2008,"claim":"Linked CDK13 to viral mRNA splicing control by showing it binds HIV-1 Tat and shifts viral splicing via ASF/SF2 phosphorylation, suppressing virus production.","evidence":"Reciprocal Co-IP, siRNA knockdown, viral production and splicing assays","pmids":["18480452"],"confidence":"Medium","gaps":["Direct kinase assay on ASF/SF2 not shown","Cyclin dependence of the activity not defined"]},{"year":2014,"claim":"Placed Cdk13 upstream of Cdk5 in neuronal axon outgrowth, revealing a developmental role distinct from general transcription.","evidence":"siRNA knockdown, in situ hybridization, microarray, and Cdk5 overexpression rescue in P19 and cortical neurons","pmids":["24999027"],"confidence":"Medium","gaps":["Mechanism by which CDK13 controls Cdk5 expression not defined","Direct substrates in neurons not identified"]},{"year":2015,"claim":"Defined CDK13 as a bona fide Cyclin K-dependent CTD kinase, providing the structural basis and substrate specificity (Ser2/Ser5 with Ser7 priming) for its transcriptional role.","evidence":"2.0 A crystal structure of Cdk13/CyclinK and in vitro kinase assays with recombinant proteins","pmids":["26748711"],"confidence":"High","gaps":["In vivo genome-wide CTD targets not mapped in this study","Functional distinction from CDK12 not addressed"]},{"year":2015,"claim":"Connected CDK13/Cyclin K to RNA processing genome-wide, showing knockdown preferentially impairs snoRNA gene expression and processing through physical association with RNA processing factors.","evidence":"Flag-tag AP-MS, RNA-seq, and siRNA knockdown","pmids":["25561469"],"confidence":"High","gaps":["Direct phosphorylation targets among processing factors not pinpointed","Mechanism of snoRNA gene selectivity unknown"]},{"year":2016,"claim":"Provided a chemical probe (THZ531) covalently targeting CDK12/CDK13, demonstrating that their inhibition collapses elongating Pol II and downregulates DNA damage response and super-enhancer-driven genes.","evidence":"Co-crystallization, covalent inhibitor design, RNA-seq, Western blot","pmids":["27571479"],"confidence":"High","gaps":["Does not separate CDK13-specific from CDK12-specific transcriptional programs","Off-target cysteine reactivity not fully excluded"]},{"year":2016,"claim":"Revealed an unexpected enrichment of CDK13 in the perinucleolar compartment that excludes its known cyclins and substrates, hinting at a non-canonical structural role.","evidence":"Immunofluorescence, co-localization with PTB, and PNC prevalence quantification","pmids":["26886422"],"confidence":"Medium","gaps":["Functional significance of PNC localization unresolved","Kinase-dependence of PNC enrichment not established"]},{"year":2019,"claim":"Showed that CDK12/CDK13 loss induces intronic polyadenylation that truncates DNA damage response transcripts, mechanistically explaining the BRCAness/DNA repair deficiency phenotype.","evidence":"siRNA, SR-4835 inhibitor, RNA-seq, intronic polyadenylation analysis, DNA repair assays","pmids":["31668947"],"confidence":"High","gaps":["CDK13-only contribution versus CDK12 not isolated","Direct phosphorylation events controlling IPA not defined"]},{"year":2020,"claim":"Used analog-sensitive kinase alleles to establish that CDK13 and CDK12 are substantially redundant for global Pol II processivity, with single CDK13 inhibition affecting growth signaling and dual inhibition being lethal.","evidence":"CRISPR analog-sensitive kinase alleles, RNA-seq, POLII ChIP-seq, viability assays","pmids":["32917631"],"confidence":"High","gaps":["Unique non-redundant CDK13 substrates not catalogued here","Basis of partial functional divergence unexplained"]},{"year":2021,"claim":"Identified CDK13 as the kinase hijacked by HIV-1 Nef to phosphorylate the restriction factor SERINC5 at Ser360, enabling its surface downregulation and antiviral suppression.","evidence":"AP-MS, in vitro kinase assay with S360A mutagenesis, flow cytometry, infectivity assays","pmids":["34380030"],"confidence":"High","gaps":["Cyclin K dependence of SERINC5 phosphorylation in cells not fully dissected","Whether endogenous CDK13 phosphorylates SERINC5 without Nef unknown"]},{"year":2021,"claim":"Reported CDK13 protein interactions (E2F5) and an ADAR1-dependent A-to-I editing event that elevates nucleolar CDK13, tying CDK13 to cancer proliferation, though through weakly reconstituted mechanisms.","evidence":"Co-IP/MS for E2F5; transcriptome sequencing and localization imaging for the c.308A>G editing event","pmids":["33390186","34496885"],"confidence":"Low","gaps":["E2F5 interaction is a single Co-IP/MS without biochemical reconstitution","Functional consequence of nucleolar CDK13 redistribution not mechanistically defined"]},{"year":2023,"claim":"Identified ZC3H14 as a direct CDK13 substrate whose phosphorylation is necessary and sufficient to activate nuclear RNA surveillance, with patient melanoma mutations abolishing this function.","evidence":"Zebrafish melanoma model, phosphorylation assays, RNA stabilization measurements, sufficiency experiments","pmids":["37079685"],"confidence":"High","gaps":["Phosphosite on ZC3H14 not specified","Link between surveillance defect and full oncogenic program incomplete"]},{"year":2023,"claim":"Established CDK13 as a direct kinase for translation initiation factors, phosphorylating 4E-BP1 (Thr46) and eIF4B (Ser422) to control mRNA translation and MYC synthesis additively with mTORC1.","evidence":"In vitro kinase assay, site-directed mutagenesis, polysome profiling, pharmacological inhibition","pmids":["36882522"],"confidence":"High","gaps":["In vivo stoichiometry relative to mTORC1 unclear","Generality across cell types beyond colorectal cancer untested"]},{"year":2023,"claim":"Extended CDK13 substrate range to epitranscriptomic and transcriptional regulators, phosphorylating NSUN5 (Ser327) to drive m5C-dependent ACC1 mRNA stability, and selectively repressing PD-L1 transcription distinct from CDK12's IPA-driven role.","evidence":"Co-IP, in vitro kinase assay, m5C profiling, mRNA stability assays (NSUN5); RNAi/overexpression dissection and kinase assay (PD-L1)","pmids":["37845385","37164450"],"confidence":"Medium","gaps":["Direct CDK13 contribution to PD-L1 promoter versus elongation not fully separated","NSUN5 phosphorylation shown in single lineage"]},{"year":2023,"claim":"Defined the inhibitor mechanism for CDK12/CDK13 as allosteric destabilization of the Cyclin K interaction rather than simple active-site competition.","evidence":"Lysine reactivity profiling and native mass spectrometry with SR-4835","pmids":["37207290"],"confidence":"Medium","gaps":["Structural model of the destabilized state not resolved","Selectivity between CDK12 and CDK13 not addressed"]},{"year":2024,"claim":"Demonstrated that CDK13 inactivation drives genomic instability via transcription-replication conflicts and that CDK12-mutant tumors are synthetically lethal with CDK13 inhibition or degradation.","evidence":"CRISPR knockout, organoids, patient-derived xenografts, transcription-replication conflict assays","pmids":["39368479"],"confidence":"Medium","gaps":["Molecular trigger of the conflicts not pinpointed","Resistance mechanisms to CDK13 degraders untested"]},{"year":2026,"claim":"Further expanded the CDK13 substrate landscape to METTL16 (Ser329) and RBM39 (Ser117), coupling its kinase activity to m6A-driven lipogenic mRNA stability and to RAD50-mediated DNA repair and chemoresistance, and mechanistically linked CDK12/13-dependent elongation to replication fork progression.","evidence":"In vitro kinase assays with mutagenesis, m6A/RNA stability assays, phosphoproteomics, RNAPII pSer2 ChIP-seq, replication fork assays, xenografts","pmids":["41680470","41997449","41882177"],"confidence":"Medium","gaps":["Each substrate validated in a single cancer context","Hierarchy among CDK13's many non-transcriptional substrates unresolved"]},{"year":null,"claim":"It remains unresolved which CDK13 functions are uniquely non-redundant with CDK12 and how its many direct substrates are prioritized in a given cell.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified map of CDK13-specific versus CDK12-shared substrates","Mechanism coupling transcription elongation to replication fork dynamics incompletely defined","No timeline evidence of a CDK13-causative Mendelian disease via direct mutation/rescue"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,8,9,10,12,19,20]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,6,16]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,9,12]},{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[0]}],"localization":[{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[3]},{"term_id":"GO:0005730","term_label":"nucleolus","supporting_discovery_ids":[14,15]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,6,16]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[1,7,8,10,19]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[7,17,20,22]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[9]}],"complexes":["CDK13-Cyclin K"],"partners":["CCNK","CCNL1","CCNL2","ZC3H14","RBM39","NSUN5","METTL16","SERINC5"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q14004","full_name":"Cyclin-dependent kinase 13","aliases":["CDC2-related protein kinase 5","Cell division cycle 2-like protein kinase 5","Cell division protein kinase 13","hCDK13","Cholinesterase-related cell division controller"],"length_aa":1512,"mass_kda":164.9,"function":"Cyclin-dependent kinase which displays CTD kinase activity and is required for RNA splicing. Has CTD kinase activity by hyperphosphorylating the C-terminal heptapeptide repeat domain (CTD) of the largest RNA polymerase II subunit RPB1, thereby acting as a key regulator of transcription elongation. Required for RNA splicing, probably by phosphorylating SRSF1/SF2. Required during hematopoiesis. In case of infection by HIV-1 virus, interacts with HIV-1 Tat protein acetylated at 'Lys-50' and 'Lys-51', thereby increasing HIV-1 mRNA splicing and promoting the production of the doubly spliced HIV-1 protein Nef","subcellular_location":"Nucleus speckle","url":"https://www.uniprot.org/uniprotkb/Q14004/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CDK13","classification":"Not Classified","n_dependent_lines":132,"n_total_lines":1208,"dependency_fraction":0.10927152317880795},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000065883","cell_line_id":"CID001146","localizations":[{"compartment":"chromatin","grade":2},{"compartment":"nucleoplasm","grade":2}],"interactors":[{"gene":"CDK9","stoichiometry":10.0},{"gene":"CCNK","stoichiometry":4.0},{"gene":"PSPC1","stoichiometry":0.2},{"gene":"RPS16","stoichiometry":0.2},{"gene":"SRP68","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001146","total_profiled":1310},"omim":[{"mim_id":"617360","title":"CONGENITAL HEART DEFECTS, DYSMORPHIC FACIAL FEATURES, AND INTELLECTUAL DEVELOPMENTAL DISORDER; CHDFIDD","url":"https://www.omim.org/entry/617360"},{"mim_id":"615514","title":"CYCLIN-DEPENDENT KINASE 12; CDK12","url":"https://www.omim.org/entry/615514"},{"mim_id":"603544","title":"CYCLIN K; CCNK","url":"https://www.omim.org/entry/603544"},{"mim_id":"603309","title":"CYCLIN-DEPENDENT KINASE 13; CDK13","url":"https://www.omim.org/entry/603309"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nuclear speckles","reliability":"Supported"},{"location":"Golgi apparatus","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CDK13"},"hgnc":{"alias_symbol":["CHED","CDC2L","KIAA1791"],"prev_symbol":["CDC2L5"]},"alphafold":{"accession":"Q14004","domains":[{"cath_id":"3.30.200.20","chopping":"697-794","consensus_level":"medium","plddt":86.2973,"start":697,"end":794},{"cath_id":"1.10.510.10","chopping":"797-1029","consensus_level":"high","plddt":94.953,"start":797,"end":1029}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14004","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q14004-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q14004-F1-predicted_aligned_error_v6.png","plddt_mean":49.84},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CDK13","jax_strain_url":"https://www.jax.org/strain/search?query=CDK13"},"sequence":{"accession":"Q14004","fasta_url":"https://rest.uniprot.org/uniprotkb/Q14004.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q14004/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14004"}},"corpus_meta":[{"pmid":"27571479","id":"PMC_27571479","title":"Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.","date":"2016","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/27571479","citation_count":283,"is_preprint":false},{"pmid":"31668947","id":"PMC_31668947","title":"Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer.","date":"2019","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/31668947","citation_count":239,"is_preprint":false},{"pmid":"25561469","id":"PMC_25561469","title":"Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing.","date":"2015","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25561469","citation_count":165,"is_preprint":false},{"pmid":"32917631","id":"PMC_32917631","title":"CDK13 cooperates with CDK12 to control global RNA polymerase II processivity.","date":"2020","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/32917631","citation_count":133,"is_preprint":false},{"pmid":"26748711","id":"PMC_26748711","title":"Structural and Functional Analysis of the Cdk13/Cyclin K Complex.","date":"2015","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/26748711","citation_count":127,"is_preprint":false},{"pmid":"22512864","id":"PMC_22512864","title":"Cyclin K goes with Cdk12 and Cdk13.","date":"2012","source":"Cell division","url":"https://pubmed.ncbi.nlm.nih.gov/22512864","citation_count":95,"is_preprint":false},{"pmid":"30319007","id":"PMC_30319007","title":"Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium.","date":"2018","source":"Transcription","url":"https://pubmed.ncbi.nlm.nih.gov/30319007","citation_count":84,"is_preprint":false},{"pmid":"22912832","id":"PMC_22912832","title":"Frequent amplification of CENPF, GMNN and CDK13 genes in hepatocellular carcinomas.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22912832","citation_count":81,"is_preprint":false},{"pmid":"37845385","id":"PMC_37845385","title":"CDK13 promotes lipid deposition and prostate cancer progression by stimulating NSUN5-mediated m5C modification of ACC1 mRNA.","date":"2023","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/37845385","citation_count":72,"is_preprint":false},{"pmid":"35938508","id":"PMC_35938508","title":"Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13.","date":"2022","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35938508","citation_count":57,"is_preprint":false},{"pmid":"17261272","id":"PMC_17261272","title":"CDK13/CDC2L5 interacts with L-type cyclins and regulates alternative splicing.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/17261272","citation_count":56,"is_preprint":false},{"pmid":"16721827","id":"PMC_16721827","title":"CDC2L5, a Cdk-like kinase with RS domain, interacts with the ASF/SF2-associated protein p32 and affects splicing in vivo.","date":"2006","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16721827","citation_count":53,"is_preprint":false},{"pmid":"9740677","id":"PMC_9740677","title":"Isolation and characterization of two novel metalloproteinase genes linked to the Cdc2L locus on human chromosome 1p36.3.","date":"1998","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9740677","citation_count":51,"is_preprint":false},{"pmid":"33390186","id":"PMC_33390186","title":"CDK13 upregulation-induced formation of the positive feedback loop among circCDK13, miR-212-5p/miR-449a and E2F5 contributes to prostate carcinogenesis.","date":"2021","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/33390186","citation_count":48,"is_preprint":false},{"pmid":"18480452","id":"PMC_18480452","title":"CDK13, a new potential human immunodeficiency virus type 1 inhibitory factor regulating viral mRNA splicing.","date":"2008","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/18480452","citation_count":48,"is_preprint":false},{"pmid":"34496885","id":"PMC_34496885","title":"An ADAR1-dependent RNA editing event in the cyclin-dependent kinase CDK13 promotes thyroid cancer hallmarks.","date":"2021","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34496885","citation_count":47,"is_preprint":false},{"pmid":"9973934","id":"PMC_9973934","title":"Abnormalities in the p34cdc2-related PITSLRE protein kinase gene complex (CDC2L) on chromosome band 1p36 in melanoma.","date":"1999","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/9973934","citation_count":47,"is_preprint":false},{"pmid":"37079685","id":"PMC_37079685","title":"Oncogenic CDK13 mutations impede nuclear RNA surveillance.","date":"2023","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/37079685","citation_count":42,"is_preprint":false},{"pmid":"28807008","id":"PMC_28807008","title":"Phenotypic and molecular characterisation of CDK13-related congenital heart defects, dysmorphic facial features and intellectual developmental disorders.","date":"2017","source":"Genome medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28807008","citation_count":40,"is_preprint":false},{"pmid":"37202753","id":"PMC_37202753","title":"Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids.","date":"2023","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/37202753","citation_count":38,"is_preprint":false},{"pmid":"29021403","id":"PMC_29021403","title":"Heterozygous mutations affecting the protein kinase domain of CDK13 cause a syndromic form of developmental delay and intellectual disability.","date":"2017","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29021403","citation_count":36,"is_preprint":false},{"pmid":"35857807","id":"PMC_35857807","title":"Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer.","date":"2022","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/35857807","citation_count":34,"is_preprint":false},{"pmid":"39368479","id":"PMC_39368479","title":"CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13.","date":"2024","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39368479","citation_count":29,"is_preprint":false},{"pmid":"24999027","id":"PMC_24999027","title":"Cdk12 and Cdk13 regulate axonal elongation through a common signaling pathway that modulates Cdk5 expression.","date":"2014","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/24999027","citation_count":28,"is_preprint":false},{"pmid":"30904094","id":"PMC_30904094","title":"CDK13-related disorder.","date":"2018","source":"Advances in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30904094","citation_count":21,"is_preprint":false},{"pmid":"29393965","id":"PMC_29393965","title":"De novo variants in CDK13 associated with syndromic ID/DD: Molecular and clinical delineation of 15 individuals and a further review.","date":"2018","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29393965","citation_count":21,"is_preprint":false},{"pmid":"31297882","id":"PMC_31297882","title":"Insight into the molecular mechanism of LINC00152/miR-215/CDK13 axis in hepatocellular carcinoma progression.","date":"2019","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31297882","citation_count":20,"is_preprint":false},{"pmid":"17389615","id":"PMC_17389615","title":"Haploinsufficiency of the cdc2l gene contributes to skin cancer development in mice.","date":"2007","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/17389615","citation_count":19,"is_preprint":false},{"pmid":"26886422","id":"PMC_26886422","title":"CDK13, a Kinase Involved in Pre-mRNA Splicing, Is a Component of the Perinucleolar Compartment.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26886422","citation_count":19,"is_preprint":false},{"pmid":"36882522","id":"PMC_36882522","title":"CDK13 phosphorylates the translation machinery and promotes tumorigenic protein synthesis.","date":"2023","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/36882522","citation_count":17,"is_preprint":false},{"pmid":"35063350","id":"PMC_35063350","title":"CDK13-related disorder: Report of a series of 18 previously unpublished individuals and description of an epigenetic signature.","date":"2022","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35063350","citation_count":16,"is_preprint":false},{"pmid":"31440507","id":"PMC_31440507","title":"Mouse Model of Congenital Heart Defects, Dysmorphic Facial Features and Intellectual Developmental Disorders as a Result of Non-functional CDK13.","date":"2019","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/31440507","citation_count":16,"is_preprint":false},{"pmid":"34513922","id":"PMC_34513922","title":"CDK13-Mediated Cell Cycle Disorder Promotes Tumorigenesis of High HMGA2 Expression Gastric Cancer.","date":"2021","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/34513922","citation_count":14,"is_preprint":false},{"pmid":"34380030","id":"PMC_34380030","title":"HIV-1 Nef interacts with the cyclin K/CDK13 complex to antagonize SERINC5 for optimal viral infectivity.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/34380030","citation_count":14,"is_preprint":false},{"pmid":"29222009","id":"PMC_29222009","title":"Redefining the phenotypic spectrum of de novo heterozygous CDK13 variants: Three patients without cardiac defects.","date":"2017","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29222009","citation_count":13,"is_preprint":false},{"pmid":"37599362","id":"PMC_37599362","title":"MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma.","date":"2023","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/37599362","citation_count":11,"is_preprint":false},{"pmid":"31883531","id":"PMC_31883531","title":"One-month-old girl presenting with pseudohypoaldosteronism leading to the diagnosis of CDK13-related disorder: a case report and review of the literature.","date":"2019","source":"Journal of medical case reports","url":"https://pubmed.ncbi.nlm.nih.gov/31883531","citation_count":9,"is_preprint":false},{"pmid":"37207290","id":"PMC_37207290","title":"Structural Mass Spectrometry Probes the Inhibitor-Induced Allosteric Activation of CDK12/CDK13-Cyclin K Dissociation.","date":"2023","source":"Journal of the American Chemical Society","url":"https://pubmed.ncbi.nlm.nih.gov/37207290","citation_count":8,"is_preprint":false},{"pmid":"37164450","id":"PMC_37164450","title":"AR-A014418 regulates intronic polyadenylation and transcription of PD-L1 through inhibiting CDK12 and CDK13 in tumor cells.","date":"2023","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37164450","citation_count":7,"is_preprint":false},{"pmid":"35043535","id":"PMC_35043535","title":"The utility of DNA methylation signatures in directing genome sequencing workflow: Kabuki syndrome and CDK13-related disorder.","date":"2022","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/35043535","citation_count":7,"is_preprint":false},{"pmid":"39533070","id":"PMC_39533070","title":"Physiological and pathological roles of the transcriptional kinases CDK12 and CDK13 in the central nervous system.","date":"2024","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/39533070","citation_count":5,"is_preprint":false},{"pmid":"33879837","id":"PMC_33879837","title":"Wolfram-like syndrome with bicuspid aortic valve due to a homozygous missense variant in CDK13.","date":"2021","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33879837","citation_count":5,"is_preprint":false},{"pmid":"37351084","id":"PMC_37351084","title":"A Prenatal Presentation of CDK13-Related Disorder with a Novel Pathogenic Variant.","date":"2023","source":"Case reports in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37351084","citation_count":4,"is_preprint":false},{"pmid":"39971730","id":"PMC_39971730","title":"CDK13-Related Disorder: Novel Insights From A Series of 27 Cases and Recommendations for Clinical Management.","date":"2025","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/39971730","citation_count":3,"is_preprint":false},{"pmid":"39488295","id":"PMC_39488295","title":"Methionine restriction promotes cisplatin sensitivity of gastric cancer resistant cells by down-regulating circ-CDK13 level.","date":"2024","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/39488295","citation_count":3,"is_preprint":false},{"pmid":"41680470","id":"PMC_41680470","title":"CDK13 drives clear cell renal carcinoma through METTL16-mediated m6A modification of ACLY mRNA.","date":"2026","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41680470","citation_count":2,"is_preprint":false},{"pmid":"38835016","id":"PMC_38835016","title":"ARID1A loss promotes RNA editing of CDK13 in an ADAR1-dependent manner.","date":"2024","source":"BMC biology","url":"https://pubmed.ncbi.nlm.nih.gov/38835016","citation_count":2,"is_preprint":false},{"pmid":"37197505","id":"PMC_37197505","title":"Cyclin O promotes lung cancer progression and cetuximab resistance via cell cycle regulation and CDK13 interaction.","date":"2023","source":"Journal of thoracic disease","url":"https://pubmed.ncbi.nlm.nih.gov/37197505","citation_count":2,"is_preprint":false},{"pmid":"41687544","id":"PMC_41687544","title":"Roles of CDK12/CDK13 and development of inhibitors and degraders.","date":"2026","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/41687544","citation_count":0,"is_preprint":false},{"pmid":"41882177","id":"PMC_41882177","title":"CDK12/CDK13 inhibition disrupts transcriptional elongation and replication fork progression in glioblastoma.","date":"2026","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41882177","citation_count":0,"is_preprint":false},{"pmid":"41491919","id":"PMC_41491919","title":"CDK12 and CDK13 in oncology: from RNA regulation to therapeutic targeting.","date":"2026","source":"Cellular oncology (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/41491919","citation_count":0,"is_preprint":false},{"pmid":"38549490","id":"PMC_38549490","title":"Deciphering congenital heart defects, facial dysmorphism and intellectual developmental disorder (CHDFIDD) associated with constitutional CDK13 pathogenic variants - case report and literature review.","date":"2023","source":"Annals of agricultural and environmental medicine : AAEM","url":"https://pubmed.ncbi.nlm.nih.gov/38549490","citation_count":0,"is_preprint":false},{"pmid":"41997449","id":"PMC_41997449","title":"Phosphorylation of RBM39 by CDK13 stabilizes RAD50 mRNA to drive cisplatin resistance in endometrial cancer.","date":"2026","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/41997449","citation_count":0,"is_preprint":false},{"pmid":"39800774","id":"PMC_39800774","title":"Validation of a hypomorphic variant in CDK13 as the cause of CHDFIDD with autosomal recessive inheritance through determination of an episignature.","date":"2025","source":"Clinical epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/39800774","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.07.16.603734","title":"Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies","date":"2024-07-19","source":"bioRxiv","url":"https://doi.org/10.1101/2024.07.16.603734","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":27479,"output_tokens":5516,"usd":0.082588,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14110,"output_tokens":5677,"usd":0.106237,"stage2_stop_reason":"end_turn"},"total_usd":0.188825,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2015,\n      \"finding\": \"CDK13 forms a complex with Cyclin K and phosphorylates both Ser2 and Ser5 of the RNA polymerase II CTD, with a preference for substrates bearing Ser7 pre-phosphorylation at a C-terminal position. The crystal structure of Cdk13/CyclinK was determined at 2.0 Å resolution, revealing a C-terminal extension helix with a polybasic cluster and a DCHEL motif that interacts with bound ATP.\",\n      \"method\": \"Crystal structure determination (2.0 Å), in vitro kinase assays with recombinant proteins\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure combined with in vitro kinase activity assays in a single rigorous study\",\n      \"pmids\": [\"26748711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CDK13, isolated as a Flag-tagged complex, associates with numerous RNA processing factors. Knockdown of CDK13 or its cyclin partner CCNK preferentially affects expression of snoRNA genes and leads to defects in RNA processing, and CDK13 physically interacts with RNA processing factors.\",\n      \"method\": \"Flag-tag affinity purification/mass spectrometry, RNA-seq, siRNA knockdown\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal AP-MS identification of interactors combined with transcriptomic knockdown phenotype, single lab but two orthogonal methods\",\n      \"pmids\": [\"25561469\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CDK13 (CDC2L5) interacts with L-type cyclins (Cyclin L1/L2) via its kinase domain; CDK13 and L-type cyclins modulate each other's subcellular localization. Overexpression of CDK13 alters the splicing pattern of E1a minigene reporter transcripts in a dose-dependent manner, and this effect is counteracted by SF2/ASF and SC35.\",\n      \"method\": \"Co-immunoprecipitation, subcellular localization imaging, minigene splicing reporter assay in HEK293T cells\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — single Co-IP plus functional splicing assay, single lab, two orthogonal methods\",\n      \"pmids\": [\"17261272\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CDK13 (CDC2L5) localizes to the nucleoplasm, with enrichment in nuclear speckles dependent on the N-terminal RS domain. CDK13 directly interacts with the ASF/SF2-associated protein p32. Overexpression of CDK13 constructs disturbs constitutive splicing and switches alternative splice site selection in vivo.\",\n      \"method\": \"Subcellular fractionation/immunofluorescence, in vitro GST pulldown, in vivo splicing assays\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding assay plus localization experiment with functional splice-site consequence, single lab\",\n      \"pmids\": [\"16721827\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CDK13 interacts with HIV-1 Tat both in vivo (co-immunoprecipitation) and in vitro. CDK13 increases HIV-1 mRNA splicing, favors production of the doubly spliced Nef protein, decreases production of viral proteins Gag and Env, and suppresses virus production. CDK13 mediates its effect on splicing through phosphorylation of ASF/SF2.\",\n      \"method\": \"Co-immunoprecipitation, in vitro binding, siRNA knockdown, viral production assays, splicing assays\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, functional siRNA rescue, and splicing mechanistic follow-up, single lab\",\n      \"pmids\": [\"18480452\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"THZ531, a covalent inhibitor, irreversibly targets a cysteine residue located outside the kinase domain of CDK12 (and by analogy CDK13, as revealed by co-crystallization with CDK12–Cyclin K). THZ531 causes loss of elongating and hyperphosphorylated RNA Pol II and substantially decreases expression of DNA damage response genes and super-enhancer-associated transcription factor genes.\",\n      \"method\": \"Co-crystallization, covalent inhibitor design, RNA-seq, Western blot\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — structural co-crystallization with functional transcriptomic validation; CDK13 inhibition confirmed alongside CDK12\",\n      \"pmids\": [\"27571479\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CDK13 and CDK12 are substantially redundant regulators of global RNA Pol II processivity and transcription elongation. Single inhibition of CDK13 induces transcriptional changes associated with cellular growth signaling pathways with minimal effects on cell viability; dual CDK12/CDK13 inhibition potently induces cell death associated with widespread use of alternative 3′ polyadenylation sites, loss of POLII CTD phosphorylation, and greatly reduced POLII elongation rates.\",\n      \"method\": \"CRISPR-Cas9 analog-sensitive kinase alleles, RNA-seq, POLII ChIP-seq, cell viability assays\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — analog-sensitive kinase system (highly specific), genome-wide transcriptomic and ChIP analyses, mechanistic epistasis between CDK12 and CDK13\",\n      \"pmids\": [\"32917631\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Inhibition or loss of CDK12/CDK13 triggers intronic polyadenylation site cleavage that suppresses expression of core DNA damage response proteins, creating a BRCAness phenotype with deficiencies in DNA damage repair.\",\n      \"method\": \"siRNA knockdown, CDK12/13 inhibitor SR-4835, RNA-seq, intronic polyadenylation analysis, DNA damage repair assays\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (genetic KD and pharmacological inhibition), genome-wide RNA-seq, functional DNA repair assay\",\n      \"pmids\": [\"31668947\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CDK13 is required for ZC3H14 phosphorylation, which is necessary and sufficient to promote nuclear RNA degradation. Mutant CDK13 (patient melanoma mutations) fails to activate nuclear RNA surveillance, causing aberrant protein-coding transcripts to be stabilized and translated.\",\n      \"method\": \"Zebrafish melanoma model, phosphorylation assays, RNA stabilization measurements, forced aberrant RNA expression\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo zebrafish disease model, identification of direct substrate ZC3H14, rescue/sufficiency experiments with multiple orthogonal approaches\",\n      \"pmids\": [\"37079685\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CDK13 directly phosphorylates translation initiation factors 4E-BP1 (at Thr46) and eIF4B (at Ser422). CDK13 inhibition disrupts mRNA translation and reduces MYC oncoprotein synthesis in colorectal cancer cells. CDK13 and mTORC1 have additive effects on 4E-BP1/eIF4B phosphorylation.\",\n      \"method\": \"In vitro kinase assay, site-specific mutagenesis, polysome profiling, pharmacological inhibition, Western blot\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay with mutagenesis identifying phosphorylation sites, polysome profiling as orthogonal functional readout, single lab\",\n      \"pmids\": [\"36882522\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CDK13 interacts with and phosphorylates RNA methyltransferase NSUN5 at Ser327. Phosphorylated NSUN5 catalyzes m5C modification of ACC1 mRNA; the m5C-modified ACC1 mRNA binds ALYREF to enhance mRNA stability and nuclear export, increasing ACC1 expression and lipid deposition in prostate cancer cells.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, m5C RNA methylation profiling, mRNA stability assays, gain/loss-of-function studies\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus in vitro kinase assay with identified phosphorylation site and downstream m5C functional consequence, single lab\",\n      \"pmids\": [\"37845385\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CDK13 interacts with E2F5; this interaction promotes PCa cell proliferation. Transcriptional activation of endogenous CDK13 promotes E2F5 protein expression by facilitating circCDK13 formation (note: the circCDK13-miRNA sponge mechanism is a non-protein product; the CDK13–E2F5 protein interaction is the canonical mechanistic finding here).\",\n      \"method\": \"Co-immunoprecipitation coupled with mass spectrometry, loss-of-function and gain-of-function assays\",\n      \"journal\": \"Journal of experimental & clinical cancer research : CR\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single Co-IP/MS identification of E2F5 interaction, single lab, no biochemical reconstitution\",\n      \"pmids\": [\"33390186\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"HIV-1 Nef recruits the Cyclin K/CDK13 complex (identified by affinity purification/mass spectrometry). CycK/CDK13 phosphorylates SERINC5 at Ser360, and this phosphorylation is required for Nef-mediated downregulation of SERINC5 from the cell surface and suppression of its antiviral activity. S360 phosphorylation increases Nef–SERINC5 interaction.\",\n      \"method\": \"Affinity purification/mass spectrometry, in vitro kinase assay, chimeric CD8-SERINC5 constructs, flow cytometry, viral infectivity assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — AP-MS complex identification followed by in vitro kinase assay with mutagenesis (S360A), functional rescue experiments, mechanistic chain established\",\n      \"pmids\": [\"34380030\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Knockdown of Cdk13 in neuronal models (P19 cells and primary cortical neurons) reduces axonal elongation. Cdk13 depletion significantly reduces Cdk5 expression at both mRNA and protein levels. Overexpression of Cdk5 partially rescues the neurite outgrowth defect caused by Cdk13 depletion, placing Cdk13 upstream of Cdk5 in a common signaling pathway.\",\n      \"method\": \"siRNA knockdown, in situ hybridization, Western blot, microarray, Cdk5 overexpression rescue, P19 neuronal differentiation model\",\n      \"journal\": \"Experimental neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis by rescue experiment (Cdk5 OE rescues Cdk13 KD), multiple readouts, single lab\",\n      \"pmids\": [\"24999027\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CDK13 is enriched in the perinucleolar compartment (PNC) throughout the cell cycle, co-localizing with PTB. Neither Cyclin K, Cyclin L (known CDK13 partners), nor CDK13's potential kinase substrates accumulate in PNC. CDK13 overexpression increases PNC prevalence, suggesting CDK13 contributes to PNC formation.\",\n      \"method\": \"Immunofluorescence microscopy, co-localization analysis, PNC prevalence quantification\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct localization by immunofluorescence with functional consequence (PNC prevalence), single lab, replicated across cell cycle stages\",\n      \"pmids\": [\"26886422\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"An ADAR1-dependent A-to-I RNA editing event in the CDK13 coding region (c.308A>G) promotes cancer cell hallmarks (viability, proliferation, invasion). This editing event increases the nucleolar abundance of CDK13 protein and may explain ADAR1-dependent global splicing changes.\",\n      \"method\": \"Whole transcriptome sequencing, RNA editing validation, functional cell assays, subnuclear localization microscopy, gene silencing\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — editing site identified by sequencing and validated, subcellular localization shift shown by imaging with functional consequence, single lab\",\n      \"pmids\": [\"34496885\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CDK13 inhibition by AR-A014418 represses transcription of PD-L1. CDK12 inhibition by the same compound enhances intronic polyadenylation (IPA) of PD-L1, generating a secreted isoform. Dual CDK12/CDK13 inhibition dramatically suppresses full-length PD-L1. These roles were confirmed by RNA interference and protein overexpression of CDK12 and CDK13 individually.\",\n      \"method\": \"In vitro kinase assay with recombinant proteins, RNA interference, protein overexpression, qRT-PCR, Western blot, flow cytometry\",\n      \"journal\": \"Journal for immunotherapy of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro kinase confirmation plus RNAi/OE dissection of CDK13-specific transcriptional role, single lab\",\n      \"pmids\": [\"37164450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CDK13 inactivation drives genomic instability via transcription-replication conflicts. CDK12-mutant organoids and patient-derived xenografts are sensitive to CDK13 inhibition or degradation, establishing synthetic lethality between CDK12 loss and CDK13 inhibition.\",\n      \"method\": \"CRISPR knockout, organoid models, patient-derived xenografts, CDK13 inhibitor/degrader treatment, transcription-replication conflict assays\",\n      \"journal\": \"Cell reports. Medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo PDX models plus mechanistic transcription-replication conflict assays, single lab\",\n      \"pmids\": [\"39368479\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"The inhibitor SR-4835 binding to CDK12/CDK13 greatly destabilizes their interaction with Cyclin K in an allosteric manner (not simply active-site competition), as revealed by lysine reactivity profiling and native mass spectrometry.\",\n      \"method\": \"Structural mass spectrometry (lysine reactivity profiling + native MS)\",\n      \"journal\": \"Journal of the American Chemical Society\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two orthogonal structural MS methods revealing allosteric mechanism, single lab\",\n      \"pmids\": [\"37207290\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"CDK13 directly phosphorylates METTL16 at Ser329, augmenting its catalytic activity to install m6A modifications on ACLY mRNA. These m6A marks are recognized by YTHDC2, stabilizing ACLY mRNA and increasing acetyl-CoA production to fuel lipogenesis in clear cell renal cell carcinoma.\",\n      \"method\": \"In vitro kinase assay, m6A profiling, mRNA stability assays, gain/loss-of-function, in vivo xenograft models\",\n      \"journal\": \"Experimental & molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro kinase assay identifying phosphorylation site plus m6A functional axis, single lab\",\n      \"pmids\": [\"41680470\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"CDK13 directly phosphorylates RBM39 at Ser117. This phosphorylation enhances RBM39 binding to and stabilization of RAD50 mRNA, increasing RAD50 protein levels and promoting DNA damage repair, thereby conferring cisplatin resistance in endometrial cancer.\",\n      \"method\": \"Phosphoproteomic analysis, in vitro kinase assay, RNA binding/stability assays, loss-of-function studies, in vivo xenograft models\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phosphoproteomic identification followed by direct in vitro kinase validation and mRNA stabilization assays, single lab\",\n      \"pmids\": [\"41997449\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Cyclin O (CCNO) interacts with CDK13 (by co-immunoprecipitation) and promotes proliferation signaling activation in lung adenocarcinoma; a CDK13 inhibitor abrogates the oncological effect of CCNO overexpression.\",\n      \"method\": \"Co-immunoprecipitation, Western blot, CDK13 inhibitor treatment, xenograft model\",\n      \"journal\": \"Journal of thoracic disease\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single Co-IP identifying CCNO-CDK13 interaction, single lab, no biochemical reconstitution of the complex\",\n      \"pmids\": [\"37197505\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"CDK12/CDK13 inhibition in glioblastoma stem cells (GSCs) causes rapid, genome-wide loss of RNAPII CTD Ser2 phosphorylation, abolishing transcriptional elongation. Unexpectedly, CDK12/CDK13 inhibition also arrests DNA replication fork progression, preceding DNA damage response activation, directly linking RNAPII elongation to replication fork dynamics.\",\n      \"method\": \"CDK12/13 inhibitor treatment, RNAPII pSer2 ChIP-seq, DNA replication fork assays, RNA-seq, xenograft models\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome-wide ChIP-seq plus orthogonal replication fork assays establishing mechanistic link, single lab\",\n      \"pmids\": [\"41882177\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CDK13 is a transcriptional cyclin-dependent kinase that forms an active heterodimer with Cyclin K; it phosphorylates Ser2 and Ser5 of the RNA Pol II CTD to promote transcriptional elongation and processivity (redundantly with CDK12), regulates alternative splicing and RNA processing through interactions with SR proteins and RNA processing factors, phosphorylates ZC3H14 to activate nuclear RNA surveillance, and directly phosphorylates non-transcriptional substrates including translation initiation factors 4E-BP1/eIF4B, the RNA methyltransferases NSUN5 and METTL16, and the RNA-binding protein RBM39, thereby linking CDK13 kinase activity to control of mRNA translation, m5C/m6A epitranscriptomic modification, and mRNA stability.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CDK13 is a transcriptional cyclin-dependent kinase that pairs with Cyclin K to phosphorylate Ser2 and Ser5 of the RNA polymerase II C-terminal domain, driving transcriptional elongation and processivity [#0]. Its crystal structure with Cyclin K reveals a C-terminal extension helix bearing a polybasic cluster and a DCHEL motif that contacts bound ATP [#0]. CDK13 functions largely redundantly with CDK12 in controlling global Pol II elongation: single CDK13 inhibition perturbs growth-signaling transcripts with little effect on viability, whereas dual CDK12/CDK13 inhibition collapses CTD phosphorylation, slows elongation, and triggers widespread alternative 3' polyadenylation and cell death [#6]. Loss of CDK12/CDK13 activity promotes intronic polyadenylation that truncates DNA damage response genes, producing a BRCAness phenotype, and drives genomic instability through transcription–replication conflicts and stalled replication forks [#7, #22], a vulnerability that underlies synthetic lethality between CDK12 loss and CDK13 inhibition [#17]. Beyond elongation, CDK13 shapes RNA processing and splicing through association with RNA processing factors and SR proteins: it interacts with the ASF/SF2-associated protein p32, localizes to nuclear speckles via its N-terminal RS domain, and alters splice-site selection [#1, #3], and it activates nuclear RNA surveillance by phosphorylating ZC3H14 to promote degradation of aberrant transcripts [#8]. CDK13 additionally phosphorylates non-transcriptional substrates, including the translation factors 4E-BP1 (Thr46) and eIF4B (Ser422) to control mRNA translation and MYC synthesis [#9], the RNA methyltransferases NSUN5 (Ser327) and METTL16 (Ser329) to direct m5C and m6A modifications that stabilize lipogenic mRNAs [#10, #19], and RBM39 (Ser117) to stabilize RAD50 mRNA and promote DNA repair [#20]. CDK13 is also exploited by HIV-1, where the Cyclin K/CDK13 complex phosphorylates SERINC5 (Ser360) to enable Nef-mediated antagonism of this antiviral factor [#12].\",\n  \"teleology\": [\n    {\n      \"year\": 2006,\n      \"claim\": \"Established CDK13 as a nuclear speckle-associated factor whose RS domain governs localization and whose activity influences constitutive and alternative splicing, framing it as a splicing regulator before its kinase partner was defined.\",\n      \"evidence\": \"Subcellular fractionation/immunofluorescence, GST pulldown with p32, and in vivo splicing assays\",\n      \"pmids\": [\"16721827\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not identify the catalytic substrate driving splice-site switching\", \"Cyclin partner and kinase activity not established here\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identified L-type cyclins as CDK13 binding partners through its kinase domain and showed dose-dependent splicing modulation counteracted by SR proteins, connecting CDK13 to the SR protein splicing machinery.\",\n      \"evidence\": \"Co-immunoprecipitation, localization imaging, and E1a minigene splicing reporter in HEK293T\",\n      \"pmids\": [\"17261272\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct phosphorylation of SR proteins not demonstrated\", \"Functional relevance of Cyclin L versus Cyclin K complexes unresolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Linked CDK13 to viral mRNA splicing control by showing it binds HIV-1 Tat and shifts viral splicing via ASF/SF2 phosphorylation, suppressing virus production.\",\n      \"evidence\": \"Reciprocal Co-IP, siRNA knockdown, viral production and splicing assays\",\n      \"pmids\": [\"18480452\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct kinase assay on ASF/SF2 not shown\", \"Cyclin dependence of the activity not defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Placed Cdk13 upstream of Cdk5 in neuronal axon outgrowth, revealing a developmental role distinct from general transcription.\",\n      \"evidence\": \"siRNA knockdown, in situ hybridization, microarray, and Cdk5 overexpression rescue in P19 and cortical neurons\",\n      \"pmids\": [\"24999027\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which CDK13 controls Cdk5 expression not defined\", \"Direct substrates in neurons not identified\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined CDK13 as a bona fide Cyclin K-dependent CTD kinase, providing the structural basis and substrate specificity (Ser2/Ser5 with Ser7 priming) for its transcriptional role.\",\n      \"evidence\": \"2.0 A crystal structure of Cdk13/CyclinK and in vitro kinase assays with recombinant proteins\",\n      \"pmids\": [\"26748711\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo genome-wide CTD targets not mapped in this study\", \"Functional distinction from CDK12 not addressed\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Connected CDK13/Cyclin K to RNA processing genome-wide, showing knockdown preferentially impairs snoRNA gene expression and processing through physical association with RNA processing factors.\",\n      \"evidence\": \"Flag-tag AP-MS, RNA-seq, and siRNA knockdown\",\n      \"pmids\": [\"25561469\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct phosphorylation targets among processing factors not pinpointed\", \"Mechanism of snoRNA gene selectivity unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Provided a chemical probe (THZ531) covalently targeting CDK12/CDK13, demonstrating that their inhibition collapses elongating Pol II and downregulates DNA damage response and super-enhancer-driven genes.\",\n      \"evidence\": \"Co-crystallization, covalent inhibitor design, RNA-seq, Western blot\",\n      \"pmids\": [\"27571479\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not separate CDK13-specific from CDK12-specific transcriptional programs\", \"Off-target cysteine reactivity not fully excluded\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Revealed an unexpected enrichment of CDK13 in the perinucleolar compartment that excludes its known cyclins and substrates, hinting at a non-canonical structural role.\",\n      \"evidence\": \"Immunofluorescence, co-localization with PTB, and PNC prevalence quantification\",\n      \"pmids\": [\"26886422\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional significance of PNC localization unresolved\", \"Kinase-dependence of PNC enrichment not established\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed that CDK12/CDK13 loss induces intronic polyadenylation that truncates DNA damage response transcripts, mechanistically explaining the BRCAness/DNA repair deficiency phenotype.\",\n      \"evidence\": \"siRNA, SR-4835 inhibitor, RNA-seq, intronic polyadenylation analysis, DNA repair assays\",\n      \"pmids\": [\"31668947\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CDK13-only contribution versus CDK12 not isolated\", \"Direct phosphorylation events controlling IPA not defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Used analog-sensitive kinase alleles to establish that CDK13 and CDK12 are substantially redundant for global Pol II processivity, with single CDK13 inhibition affecting growth signaling and dual inhibition being lethal.\",\n      \"evidence\": \"CRISPR analog-sensitive kinase alleles, RNA-seq, POLII ChIP-seq, viability assays\",\n      \"pmids\": [\"32917631\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Unique non-redundant CDK13 substrates not catalogued here\", \"Basis of partial functional divergence unexplained\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified CDK13 as the kinase hijacked by HIV-1 Nef to phosphorylate the restriction factor SERINC5 at Ser360, enabling its surface downregulation and antiviral suppression.\",\n      \"evidence\": \"AP-MS, in vitro kinase assay with S360A mutagenesis, flow cytometry, infectivity assays\",\n      \"pmids\": [\"34380030\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cyclin K dependence of SERINC5 phosphorylation in cells not fully dissected\", \"Whether endogenous CDK13 phosphorylates SERINC5 without Nef unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Reported CDK13 protein interactions (E2F5) and an ADAR1-dependent A-to-I editing event that elevates nucleolar CDK13, tying CDK13 to cancer proliferation, though through weakly reconstituted mechanisms.\",\n      \"evidence\": \"Co-IP/MS for E2F5; transcriptome sequencing and localization imaging for the c.308A>G editing event\",\n      \"pmids\": [\"33390186\", \"34496885\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"E2F5 interaction is a single Co-IP/MS without biochemical reconstitution\", \"Functional consequence of nucleolar CDK13 redistribution not mechanistically defined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified ZC3H14 as a direct CDK13 substrate whose phosphorylation is necessary and sufficient to activate nuclear RNA surveillance, with patient melanoma mutations abolishing this function.\",\n      \"evidence\": \"Zebrafish melanoma model, phosphorylation assays, RNA stabilization measurements, sufficiency experiments\",\n      \"pmids\": [\"37079685\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphosite on ZC3H14 not specified\", \"Link between surveillance defect and full oncogenic program incomplete\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established CDK13 as a direct kinase for translation initiation factors, phosphorylating 4E-BP1 (Thr46) and eIF4B (Ser422) to control mRNA translation and MYC synthesis additively with mTORC1.\",\n      \"evidence\": \"In vitro kinase assay, site-directed mutagenesis, polysome profiling, pharmacological inhibition\",\n      \"pmids\": [\"36882522\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo stoichiometry relative to mTORC1 unclear\", \"Generality across cell types beyond colorectal cancer untested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Extended CDK13 substrate range to epitranscriptomic and transcriptional regulators, phosphorylating NSUN5 (Ser327) to drive m5C-dependent ACC1 mRNA stability, and selectively repressing PD-L1 transcription distinct from CDK12's IPA-driven role.\",\n      \"evidence\": \"Co-IP, in vitro kinase assay, m5C profiling, mRNA stability assays (NSUN5); RNAi/overexpression dissection and kinase assay (PD-L1)\",\n      \"pmids\": [\"37845385\", \"37164450\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct CDK13 contribution to PD-L1 promoter versus elongation not fully separated\", \"NSUN5 phosphorylation shown in single lineage\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined the inhibitor mechanism for CDK12/CDK13 as allosteric destabilization of the Cyclin K interaction rather than simple active-site competition.\",\n      \"evidence\": \"Lysine reactivity profiling and native mass spectrometry with SR-4835\",\n      \"pmids\": [\"37207290\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural model of the destabilized state not resolved\", \"Selectivity between CDK12 and CDK13 not addressed\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Demonstrated that CDK13 inactivation drives genomic instability via transcription-replication conflicts and that CDK12-mutant tumors are synthetically lethal with CDK13 inhibition or degradation.\",\n      \"evidence\": \"CRISPR knockout, organoids, patient-derived xenografts, transcription-replication conflict assays\",\n      \"pmids\": [\"39368479\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular trigger of the conflicts not pinpointed\", \"Resistance mechanisms to CDK13 degraders untested\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Further expanded the CDK13 substrate landscape to METTL16 (Ser329) and RBM39 (Ser117), coupling its kinase activity to m6A-driven lipogenic mRNA stability and to RAD50-mediated DNA repair and chemoresistance, and mechanistically linked CDK12/13-dependent elongation to replication fork progression.\",\n      \"evidence\": \"In vitro kinase assays with mutagenesis, m6A/RNA stability assays, phosphoproteomics, RNAPII pSer2 ChIP-seq, replication fork assays, xenografts\",\n      \"pmids\": [\"41680470\", \"41997449\", \"41882177\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Each substrate validated in a single cancer context\", \"Hierarchy among CDK13's many non-transcriptional substrates unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved which CDK13 functions are uniquely non-redundant with CDK12 and how its many direct substrates are prioritized in a given cell.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified map of CDK13-specific versus CDK12-shared substrates\", \"Mechanism coupling transcription elongation to replication fork dynamics incompletely defined\", \"No timeline evidence of a CDK13-causative Mendelian disease via direct mutation/rescue\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 8, 9, 10, 12, 19, 20]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 6, 16]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 9, 12]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [14, 15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 6, 16]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [1, 7, 8, 10, 19]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [7, 17, 20, 22]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [9]}\n    ],\n    \"complexes\": [\"CDK13-Cyclin K\"],\n    \"partners\": [\"CCNK\", \"CCNL1\", \"CCNL2\", \"ZC3H14\", \"RBM39\", \"NSUN5\", \"METTL16\", \"SERINC5\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}